用户名:
密 码:
注册
|
忘记密码?
首 页
药品信息
药品检索
全部药品
适应症分类
热门药品
专利信息
专利检索
专利权人导航
专利权人分组导航
分类查询
IPC导航
热门检索
专利分析
概况
申请趋势分析
申请人分析
发明人分析
IPC分析
项目文档
项目
个人项目
文档
个人文档
企业文档
公共文档
标签
互动
特色功能
广州科技订制咨询
特色资讯
医药新闻
帮助中心
关于本软件
药品
文档
专利
新闻
所有专利
选择导航
专利权人导航
专利权人分组导航
分类导航
专利权人导航
Teva Pharmaceutical Industries Ltd.(680)
LES LABORATOIRES SERVIER(662)
ASTRAZENECA AB(639)
Pfizer Inc.(549)
TEVA PHARMA [IL](524)
NOVARTIS AG(523)
H. Lundbeck A/s(462)
ELI LILLY AND COMPANY(442)
Basf Aktiengesellschaft(412)
CELANESE INT CORP [US](396)
专利信息
Translation Company
查询条件
展开筛选条件
[IPC] 包含 'C'
清空条件
查询
分析
排序
公开日
公开号
申请日
申请号
中文标题
英文标题
降序
升序
翻到页码
标题
标题2
专利权人
发明人
附图
摘要
摘要2
优先权号
IPC
专利类型
首页
上页
1
2
3
4
5
6
7
8
9
10
下页
尾页
共
126757
条记录, 当前第5/12676页。
公开号
公开日
申请号
申请日
1.
US2014080787A1
2014/3/20
US201314026667
2013/9/13
专利标题
:Method for the Treatment of Neuropathies Associated with Charcot-Marie-Tooth 1A (CMT1A) Disease
专利权人
:
NAT INST OF HEALTH US DEPT OF HEALTH AND HUMAN SERVICES [US]
;
CHARCOT MARIE TOOTH ASS [US]
;
The present invention relates to compositions and methods for the treatment, prevention, and diagnosis of neuropathies due to PMP22 mis-expression in a subject having Charcot-Marie-Tooth disease, especially Charcot-Marie-Tooth 1A disease. The present invention incorporates the use of small molecule proteasome inhibitors such as, but not limited to, Bortezomib to inhibit or reduce the overexpression of the PMP2 gene.
2.
WO2014041324A1
2014/3/20
WO2013GB00380
2013/9/11
专利标题
:PROCESS FOR PREPARING OF BORTEZAMIB
专利权人
:
CIPLA LTD [IN]
;
KING LAWRENCE LOUIS [GB]
;
The present invention provides improved processes for the preparation of Bortezomib, tert-butyl[1-({(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6-methano-1,3,2-benzodioxaborol-2-yl]butyl}amino)-1-oxo-3-phenylpropan-2-yl]carbamate of formula (IV) and N-{(1S)-3-methyl-1-[(3aS,4S,6S,7aS)-3a,5,5-trimethylhexahydro-4,6- methano-1,3,2-benzodioxaborol-2-yl]butyl} phenylalanine of formula (V). Compound (IV) is prepared by coupling (1R)-3-methyl-1-[(3aS,4S,6S,7aR)-3a,5,5-trimethyl- hexah...
3.
AU2012322797A1
2014/3/20
AU20120322797
2012/10/11
专利标题
:Uses for and article of manufacture including HER2 dimerization inhibitor pertuzumab
专利权人
:
GENENTECH INC
;
The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population
4.
US2014079665A1
2014/3/20
US201214118007
2012/5/15
专利标题
:THERAPEUTIC ANTI-IGF1R COMBINATIONS
专利权人
:
MERCK SHARP & DOHME [US]
;
The present invention provides, in part, compositions including an anti-IGF1R antibody or antigen-binding fragment thereof and any one or more of cisplatin, pemetrexed, gemcitabine and/or irinotecan
5.
US2014080848A1
2014/3/20
US201314026545
2013/9/13
专利标题
:ARYL AMINE SUBSTITUTED PYRIMIDINE AND QUINAZOLINE AND THEIR USE AS ANTICANER DRUGS
专利权人
:
UNIV NAT TAIWAN [TW]
;
UNIV NAT YANG MING [TW]
;
A series of mono- and di-substituted quinazoline and pyrimidine derivatives based on the skeleton of erlotinib (an EGFR inhibitor) were synthesized and their bioactivities against hepatocellular carcinoma and human lung adenocarcinoma were evaluated.
6.
US2014081033A1
2014/3/20
US201314085458
2013/11/20
专利标题
:Novel Crystalline Form of Atorvastatin Hemi-calcium Salt, Hydrate Thereof, And Method of Producing The Same
专利权人
:
KYONGBO PHARM [KR]
;
The present invention provides a novel crystalline form of [R-(R*,R*)]-2-(4-fluorophenyl)-[beta],[delta]-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:
7.
WO2014041059A1
2014/3/20
WO2013EP68887
2013/9/12
专利标题
:PROCESS TO PRODUCE ATORVASTATIN INTERMEDIATES
专利权人
:
DSM SINOCHEM PHARM NL BV [NL]
;
The invention provides a process for the production of a compound of formula (I), said process comprising reacting a compound of formula (II) with a compound of formula (III) wherein R1 and R2 may be the same or different and are selected from H
8.
WO2014041058A1
2014/3/20
WO2013EP68886
2013/9/12
专利标题
:PROCESS TO PRODUCE ATORVASTATIN INTERMEDIATES
专利权人
:
DSM SINOCHEM PHARM NL BV [NL]
;
The invention provides a process for the production of 1 a compound of formula (I), said process comprising reacting a compound of formula (II), with a compound of formula (III), wherein R1 and R2 may be the same or different and are selected from H
9.
US2014081026A1
2014/3/20
US201214114781
2012/5/4
专利标题
:PROCESS FOR THE PRODUCTION OF SITAGLIPTIN
专利权人
:
RASPARINI MARCELLO [IT]
;
TUFARO ROBERTO ROCCO [IT]
;
MINELLI COSIMA [IT]
;
CHEMO IBERICA SA [ES]
;
A novel process is described for the synthesis of Sitagliptin, IUPAC name 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine, of formula (I).
10.
WO2014043628A1
2014/3/20
WO2013US59958
2013/9/16
专利标题
:GENES ASSOCIATED WITH DASATINIB SENSITIVITY
专利权人
:
SLOAN KETTERING INST CANCER [US]
;
Disclosed herein is a panel of seven genes, TACSTD2, TSPAN8, COL3A1, SPOCK1, SFN, KRT7, and S100A2, the expression of which, in a circulating tumor cell, isolated from the blood of a patient with castrate resistant prostate cancer (CRPC), is indicative of whether or not the patient will be responsive to therapy with dasatinib. The method includes the calculation of a sensitivity score using an equation that is weighted based upon relative expression of the gene panel to produce a separation of s...
首页
上页
1
2
3
4
5
6
7
8
9
10
下页
尾页
共
126757
条记录, 当前第5/12676页。
当前查询条件: [IPC] 包含 'C'
查询范围
在当前结果中查询
!
专利类型
发明
实用新型
外观设计
!
公开号
CN1234
!
申请号
CN1234
!
专利标题
扩展
PHARMA
!
专利权人
扩展
pfizer
发明人
!
申请日
yyyymmdd
!
公开日
yyyymmdd
优先权号
!
摘要
扩展
PHARMA
IPC
A01B
下载范围
下载第
到
条记录。
下载内容
题录信息
专利全文